High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV - 20/03/20
Doi : 10.1016/j.jinf.2019.11.018
Zaira R. Palacios-Baena a, ⁎ 
, María Paniagua-García a, Inmaculada López-Hernández a, Felipe Fernández-Cuenca a, Mª José Ríos-Villegas a, b
, María Paniagua-García a, Inmaculada López-Hernández a, Felipe Fernández-Cuenca a, Mª José Ríos-Villegas a, b a Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Sevilla (IBIS), Avda. Dr. Fedriani, No 3, 41008 Seville, Spain
b Department of Medicine, University of Seville, Seville, Spain
⁎Corresponding author.
Highlights |
• | HBV could be reactivated in HBcAb-positive and HBsAg-negative patients treated with direct-acting antivirals. |
• | Periodic monitoring of viral load of HBV during direct-acting antivirals treatment has been proposed in this review. |
• | HIV patients with HBcAb-positive should be treated with nucleoside/nucleotide analogous to avoid possible reactivations. |
Keywords : HBV reactivation, HIV–HCV coinfection, DAA, HCV
Plan
© 2019
Publié par Elsevier Masson SAS.
Vol 80 - N° 4
P. 469-496 - avril 2020 Retour au numéro
Article précédent
- Identification of a new HCV subtype 6xi among chronic hepatitis C patients in Yunnan, China
- Wei Yue, Yue Feng, Yuanyuan Jia, Yang Liu, Yaxiang Zhang, Jiawei Geng, Xueshan Xia
- The heterogeneity of influenza seasonality by subtype and lineage in China
- Cuiling Xu, Benjamin J. Cowling, Tao Chen, Lijie Wang, Ye Zhang, Dawei Huang, Lei Yang, Jing Yang, Weijuan Huang, Dayan Wang, Yuelong Shu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?